vs
AtriCure, Inc.（ATRC）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是AtriCure, Inc.的1.0倍（$143.1M vs $140.5M），GLAUKOS Corp同比增速更快（35.7% vs 13.1%），AtriCure, Inc.自由现金流更多（$18.4M vs $3.9M），过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 13.6%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
ATRC vs GKOS — 直观对比
营收规模更大
GKOS
是对方的1.0倍
$140.5M
营收增速更快
GKOS
高出22.6%
13.1%
自由现金流更多
ATRC
多$14.5M
$3.9M
两年增速更快
GKOS
近两年复合增速
13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $143.1M |
| 净利润 | — | $-133.7M |
| 毛利率 | 75.0% | -1.1% |
| 营业利润率 | 1.8% | -97.7% |
| 净利率 | — | -93.4% |
| 营收同比 | 13.1% | 35.7% |
| 净利润同比 | — | -298.0% |
| 每股收益（稀释后） | $0.04 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCGKOS
| Q4 25 | $140.5M | $143.1M | ||
| Q3 25 | $134.3M | $133.5M | ||
| Q2 25 | $136.1M | $124.1M | ||
| Q1 25 | $123.6M | $106.7M | ||
| Q4 24 | $124.3M | $105.5M | ||
| Q3 24 | $115.9M | $96.7M | ||
| Q2 24 | $116.3M | $95.7M | ||
| Q1 24 | $108.9M | $85.6M |
净利润ATRCGKOS
| Q4 25 | — | $-133.7M | ||
| Q3 25 | $-267.0K | $-16.2M | ||
| Q2 25 | $-6.2M | $-19.7M | ||
| Q1 25 | $-6.7M | $-18.1M | ||
| Q4 24 | — | $-33.6M | ||
| Q3 24 | $-7.9M | $-21.4M | ||
| Q2 24 | $-8.0M | $-50.5M | ||
| Q1 24 | $-13.3M | $-40.8M |
毛利率ATRCGKOS
| Q4 25 | 75.0% | -1.1% | ||
| Q3 25 | 75.5% | 78.4% | ||
| Q2 25 | 74.5% | 78.3% | ||
| Q1 25 | 74.9% | 77.2% | ||
| Q4 24 | 74.5% | 72.9% | ||
| Q3 24 | 74.9% | 76.6% | ||
| Q2 24 | 74.7% | 76.4% | ||
| Q1 24 | 74.7% | 76.3% |
营业利润率ATRCGKOS
| Q4 25 | 1.8% | -97.7% | ||
| Q3 25 | 0.2% | -12.3% | ||
| Q2 25 | -4.5% | -18.3% | ||
| Q1 25 | -4.8% | -19.4% | ||
| Q4 24 | -11.7% | -27.2% | ||
| Q3 24 | -6.4% | -25.5% | ||
| Q2 24 | -6.2% | -31.3% | ||
| Q1 24 | -10.0% | -45.6% |
净利率ATRCGKOS
| Q4 25 | — | -93.4% | ||
| Q3 25 | -0.2% | -12.2% | ||
| Q2 25 | -4.5% | -15.8% | ||
| Q1 25 | -5.5% | -17.0% | ||
| Q4 24 | — | -31.8% | ||
| Q3 24 | -6.8% | -22.1% | ||
| Q2 24 | -6.9% | -52.8% | ||
| Q1 24 | -12.2% | -47.7% |
每股收益（稀释后）ATRCGKOS
| Q4 25 | $0.04 | $-2.34 | ||
| Q3 25 | $-0.01 | $-0.28 | ||
| Q2 25 | $-0.13 | $-0.34 | ||
| Q1 25 | $-0.14 | $-0.32 | ||
| Q4 24 | $-0.33 | $-0.56 | ||
| Q3 24 | $-0.17 | $-0.39 | ||
| Q2 24 | $-0.17 | $-1.00 | ||
| Q1 24 | $-0.28 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $90.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.9M | $656.2M |
| 总资产 | $654.2M | $893.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCGKOS
| Q4 25 | $167.4M | $90.8M | ||
| Q3 25 | $147.9M | $98.2M | ||
| Q2 25 | $117.8M | $100.8M | ||
| Q1 25 | $99.9M | $114.3M | ||
| Q4 24 | $122.7M | $169.6M | ||
| Q3 24 | $130.3M | $100.1M | ||
| Q2 24 | $114.0M | $68.1M | ||
| Q1 24 | $106.0M | $42.5M |
总债务ATRCGKOS
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — | ||
| Q1 24 | $61.9M | — |
股东权益ATRCGKOS
| Q4 25 | $491.9M | $656.2M | ||
| Q3 25 | $476.5M | $769.5M | ||
| Q2 25 | $464.5M | $765.1M | ||
| Q1 25 | $454.6M | $764.0M | ||
| Q4 24 | $461.0M | $766.9M | ||
| Q3 24 | $465.0M | $668.5M | ||
| Q2 24 | $462.1M | $665.2M | ||
| Q1 24 | $456.3M | $450.7M |
总资产ATRCGKOS
| Q4 25 | $654.2M | $893.5M | ||
| Q3 25 | $635.4M | $999.4M | ||
| Q2 25 | $608.8M | $987.0M | ||
| Q1 25 | $591.6M | $966.2M | ||
| Q4 24 | $609.3M | $974.8M | ||
| Q3 24 | $615.1M | $926.5M | ||
| Q2 24 | $597.3M | $919.7M | ||
| Q1 24 | $591.6M | $933.3M |
负债/权益比ATRCGKOS
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $3.9M |
| 自由现金流率自由现金流/营收 | 13.1% | 2.7% |
| 资本支出强度资本支出/营收 | 1.1% | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $48.3M | $-22.5M |
8季度趋势，按日历期对齐
经营现金流ATRCGKOS
| Q4 25 | $20.0M | $6.8M | ||
| Q3 25 | $26.7M | $-10.1M | ||
| Q2 25 | $21.6M | $7.0M | ||
| Q1 25 | $-11.0M | $-18.5M | ||
| Q4 24 | $5.8M | $507.0K | ||
| Q3 24 | $20.0M | $-9.6M | ||
| Q2 24 | $7.4M | $-18.4M | ||
| Q1 24 | $-21.0M | $-33.9M |
自由现金流ATRCGKOS
| Q4 25 | $18.4M | $3.9M | ||
| Q3 25 | $24.1M | $-11.7M | ||
| Q2 25 | $19.0M | $5.8M | ||
| Q1 25 | $-13.2M | $-20.5M | ||
| Q4 24 | $3.1M | $-1.2M | ||
| Q3 24 | $16.4M | $-11.0M | ||
| Q2 24 | $5.0M | $-20.5M | ||
| Q1 24 | $-23.8M | $-34.8M |
自由现金流率ATRCGKOS
| Q4 25 | 13.1% | 2.7% | ||
| Q3 25 | 18.0% | -8.8% | ||
| Q2 25 | 13.9% | 4.7% | ||
| Q1 25 | -10.7% | -19.2% | ||
| Q4 24 | 2.5% | -1.2% | ||
| Q3 24 | 14.1% | -11.4% | ||
| Q2 24 | 4.3% | -21.4% | ||
| Q1 24 | -21.9% | -40.7% |
资本支出强度ATRCGKOS
| Q4 25 | 1.1% | 2.0% | ||
| Q3 25 | 1.9% | 1.2% | ||
| Q2 25 | 2.0% | 0.9% | ||
| Q1 25 | 1.8% | 1.8% | ||
| Q4 24 | 2.2% | 1.6% | ||
| Q3 24 | 3.1% | 1.5% | ||
| Q2 24 | 2.1% | 2.2% | ||
| Q1 24 | 2.5% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
